A Semi-automated Method For The Liver Lesion ...

Spread Of Ctx-m-15 Extended Spectrum β-lactama...

Interdisciplinary Research Training

Current Status, Challenges And Needs For Pilgri...

The Political Economy Of Ebola Virus Disease (e...

0 votes
Simeprevir For The Treatment Of Hcv Infection
Author: Laure Izquierdo, François Helle, Catherine François, Sandrine Castelain, Gilles Duverlie, Etienne Brochot
9 pages
One time payment: €0.00
Required subscription: Free
Type of publication: Article
ISBN/ISSN: 1178-7066
DOI: 10.2147/52715
Follow this publisher

Share this publication:


Abstract: Simeprevir (TMC435, Olysio™), a second-generation hepatitis C virus (HCV) protease inhibitor, has been recently approved for the treatment of genotype 1 chronic hepatitis C in combination with pegylated interferon and ribavirin. This molecule has very different characteristics from first-generation protease inhibitors. Results from trials show that simeprevir is highly effective and safe, with few adverse events. We discuss the specific features of this new treatment option for HCV infection, in terms of in vitro data, pharmacological data, and clinical trials. We also discuss the impact of Q80K polymorphism at baseline. Studies evaluating interferon-free regimens with simeprevir are ongoing. Future combinations of two or more direct-acting antiviral agents, targeting different viral enzymes and with synergistic antiviral effects, will be approved, allowing treatment of pan-genotypic HCV with optimized sustained virologic responses. Simeprevir will undoubtedly be part of future treatment strategies.

Select a payment method